General
Preferred name
DORSOMORPHIN
Synonyms
Dorsomorphin dihydrochloride ()
Compound C ()
BML275 ()
BML-275 ()
BML-275 2HCl ()
Compound C dihydrochloride ()
Dorsomorphin (Compound C) 2HCl ()
Compound C 2HCl ()
BML-275 dihydrochloride ()
Dorsomorphin 2HCl ()
Dorsomorphin ()
Dorsomorphin (dihydrochloride) ()
Compound C (dihydrochloride) ()
BML-275 (dihydrochloride) ()
BML-275 2HCl,Compound C 2HCl ()
BML-275,Compound C ()
Dorsomorphin (Compound C) ()
Dorsomorphin (hydrochloride) ()
P&D ID
PD004294
CAS
1219168-18-9
866405-64-3
Tags
available
drug candidate
obsolete probe
Drug indication
Discovery agent
Drug Status
experimental
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Dorsomorphin (Compound C) dihydrochloride is a potent, selective and ATP-competitive AMPK inhibitor, with a Ki of 109 nM. Dorsomorphin dihydrochloride inhibits BMP pathway by targeting the type I receptors ALK2, ALK3, and ALK6. Dorsomorphin dihydrochloride can reverse autophagy activation and anti-inflammatory effect of Urolithin A (HY-100599).
PRICE 62
DESCRIPTION Dorsomorphin is a potent, reversible, selective AMP-activated protein kinase (AMPK) inhibitor . It is an ATP-competitive inhibitor of the catalytic α subunit of the heterotrimeric enzyme. (GtoPdb)
PRICE 63
DESCRIPTION Cdk inhibitor; potently inhibits cdk2 and cdk9 (Tocris Bioactive Compound Library)
DESCRIPTION Potent and selective AMPK inhibitor (Tocriscreen Plus)
DESCRIPTION Dorsomorphin dihydrochloride (BML-275 2HCl) is a potent, selective and ATP-competitive AMPK inhibitor (Ki: 109 nM) and does not exhibit significant activity on structurally related kinases. (TargetMol Bioactive Compound Library)
DESCRIPTION Dorsomorphin (BML-275) is an AMPK inhibitor (Ki=109 nM) that is selective and ATP-competitive. Dorsomorphin inhibits the BMP type I receptors ALK2, ALK3, and ALK6. Dorsomorphin induces autophagy, and possesses antitumor activity. (TargetMol Bioactive Compound Library)
Cell lines
2
Organisms
0
Compound Sets
18
AdooQ Bioactive Compound Library
A13720
A11970
Axon Medchem Screening Library
2150
1708
Cayman Chemical Bioactives
21207
11967
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB08597
DrugMAP
DMKYXJW
Guide to Pharmacology
4907
LINCS compound set
10399-102
Mcule NIBR MoA Box Subset
MCULE-1245787291
MedChem Express Bioactive Compound Library
HY-13418
HY-13418A
Novartis Chemogenetic Library (NIBR MoA Box)
Obsolete Compounds
dorsomorphin
ReFrame library
Selleckchem Bioactive Compound Library
dorsomorphin-2hcl
dorsomorphin
TargetMol Bioactive Compound Library
T6146
T1977
Tocris Bioactive Compound Library
3093
Tocriscreen Plus
3093
External IDs
41
Properties
(calculated by RDKit )
Molecular Weight
399.21
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
0
Rotatable Bonds
6
Ring Count
5
Aromatic Ring Count
4
cLogP
4.32
TPSA
55.55
Fraction CSP3
0.29
Chiral centers
0.0
Largest ring
6.0
QED
0.48
Structural alerts
1
historic compounds (Chemical Probes.org)
Obsolete
Related compounds
Custom attributes
(extracted from source data)
Target Type
Enzymes
Target
TGF-¦Â Receptor
ACVR1, BMPR1A, BMPR1B, EPHA2, FKBP1A, FLT1, FLT3, KDR, LCK, MKNK1, PRKAA1, RPS6KA1, SRC
BMP inhibitor
Organoid
TGF-β Receptor
AMPK,Autophagy,TGF-beta/Smad
Pathway
Autophagy
Chromatin/Epigenetic
PI3K/Akt/mTOR signaling
Stem Cells
Epigenetics
PI3K/Akt/mTOR
Stem Cell/Wnt
TGF-beta/Smad
Primary Target
AMPK
MOA
Inhibitor
AMPK inhibitor
Member status
virtual
Source data